Projects

Blood Cancers

Our team is developing new fusion proteins to improve antitumor T cell function against acute myeloid leukemia (AML).

Solid Tumors

Our new generation of fusion proteins enhance therapeutic efficacy by stimulating endogenous anticancer immunity within the solid tumor microenvironment.

Targeting the Immunosuppressive Tumor Microenvironment with Transform Switch Receptors

We are developing a toolbox of TSRs and will determine which ones best enhance therapeutic efficacy against hematological and solid tumors, to support clinical translation.

Catalyzing Endogenous Antitumor Immunity with Dual Costimulatory Receptors (DCR)

We are developing a new class of fusion proteins, called Dual Costimulatory Receptors (DCR), that combine a costimulatory ligand ectodomain with a different costimulatory signaling endodomain.

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.